 The primary objective of the trial is to evaluate against a placebo the efficacy of Cocculine administered as an adjunct to conventional treatments corticosteroids and 5-HT3 receptor antagonists for the management of nausea induced by a 1st course of adjuvant CT with FAC50, FEC100 or TAC in patients with non-metastatic breast cancer. 